Key facts
- Autonomy Bio’s last known valuation is $47.0M (Mar 2025).
- It has raised $17.0M across 1 recorded rounds; the latest was Early Stage VC ($17.0M) in Mar 2025.
- Notable investors include One Capital (Tokyo), Valhalla Ventures.
- Autonomy Bio has filed 1 Form D with the SEC, most recently Mar 2025 ($17.0M sold to 8 investors).
- Status: Privately Held (backing).
Investors
2Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Autonomy Bio
Create free account
No card required
Funding rounds
1 roundsAbout Autonomy Bio
Operator of a drug discovery company designed to develop human aging drugs. The company aims to adopt an approach that combines existing FDA-approved drug classes, enabling clients to start clinical trials while reducing development risks.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 2
- Website
- autonomybio.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Autonomy Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Autonomy Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Autonomy Bio in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.